{
  "abstract": "Objective: Our objective was to characterize the molecular–pathologic profile and recurrence patterns of endometrial cancer with pelvic lymph node isolated tumor cells (ITCs). Methods: A single-center retrospective study of patients with endometrial cancer and ITCs was conducted. Patients with concurrent lymph nodes or distant metastasis were excluded. Cases were reviewed by a gynecologic pathologist, and electronic medical records were reviewed. Descriptive statistics were performed using R 4.4.2. Results: A total of 43 patients were included, with a median follow-up time of 33 months. The majority were endometrioid carcinoma (91%) and stage I (72%). In total, 28 (65%) were MMR-proficient and p53-wild-type (MMRp p53wt), nine (21%) were MMR-deficient (MMRd), six (14%) were p53-abnormal (p53abn), and none were POLE-mutated (POLEmut). Additionally, 27 (96%) MMRp p53wt cases showed a microcystic, elongated, and fragmented (MELF) pattern of invasion. Adjuvant therapy was indicated in 38 (88%) patients; 32 (74%) received therapy and six (14%) declined. Four (9.3%) patients recurred, with a recurrence rate of 33% (2/6) for p53abn, 11% (1/9) for MMRd, and 4% (1/28) for MMRp p53wt. All recurrences were to distant sites. In the MMRp p53wt group, 16 (57%) had external beam radiation (EBRT) +/− vaginal brachytherapy (VBT), three (11%) had chemotherapy +/− radiation, and nine (32%) had no adjuvant treatment or VBT alone. Conclusions: Molecular profile is prognostically relevant in endometrial carcinoma with ITCs. ITCs in MMRp p53wt endometrioid carcinoma present a low risk of disease recurrence. As the majority of our cohort received adjuvant therapy, future work may explore de-escalating treatment in low-risk ITC cases.",
  "abstract_shown": true,
  "affiliations": [
    "Faculty of Medicine & Dentistry, University of Alberta, Edmonton, AB T6G 2R3, Canada",
    "Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB T6G 2R3, Canada",
    "Cross Cancer Institute, Department of Oncology, Faculty of Medicine & Dentistry, University of Alberta, Edmonton, AB T6G 2R3, Canada",
    "Cross Cancer Institute, Department of Obstetrics & Gynecology, Division of Gynecologic Oncology, Faculty of Medicine & Dentistry, University of Alberta, Edmonton, AB T6G 2R3, Canada"
  ],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 4,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Haley D. Frerichs",
      "orcid": "0009-0009-7267-7428"
    },
    {
      "affs": [
        1
      ],
      "name": "Cheng-Han Lee",
      "orcid": "0000-0003-2094-1222"
    },
    {
      "affs": [
        2
      ],
      "name": "Ericka Wiebe"
    },
    {
      "affs": [
        3
      ],
      "name": "Sophia Pin",
      "orcid": "0000-0003-2264-044X"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/b5kw7m1dmkbwd.bib",
  "cited_by": 0,
  "doi": "10.3390/cancers18203293",
  "fulltext_url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13702782/?tool=EBI",
  "id": "b5kw7m1dmkbwd",
  "issns": [
    "2072-6694"
  ],
  "landing_url": "https://www.mdpi.com/2072-6694/18/20/3293",
  "language": "eng",
  "licence": "CC-BY-4.0",
  "licence_label": "CC BY 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "openalex",
      "2729|Endometrial and Cervical Cancer Treatments"
    ]
  ],
  "openalex": "W7221670601",
  "pdf_url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13702782/pdf/?tool=EBI",
  "pmcid": "PMC13702782",
  "pmid": null,
  "published": "2026-10-01",
  "publisher": "MDPI AG",
  "ris": "https://research.draconitic.com/paper/b5kw7m1dmkbwd.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:19:58Z",
      "native_id": "10.3390/cancers18203293",
      "source": "crossref",
      "url": "https://www.mdpi.com/2072-6694/18/20/3293"
    },
    {
      "first_seen": "2026-10-30T12:21:47Z",
      "native_id": "PMC:PMC13702782",
      "source": "europepmc",
      "url": "https://europepmc.org/article/PMC/PMC13702782"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2729|Endometrial and Cervical Cancer Treatments",
      "subfield": "reproductive-child"
    }
  ],
  "title": "Clinicopathologic Characteristics, Molecular Profile, Treatment, and Recurrence in Endometrial Cancer with Pelvic Lymph Node Isolated Tumor Cells",
  "title_text": "Clinicopathologic Characteristics, Molecular Profile, Treatment, and Recurrence in Endometrial Cancer with Pelvic Lymph Node Isolated Tumor Cells",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T12:21:47Z",
  "url": "https://research.draconitic.com/paper/b5kw7m1dmkbwd",
  "venue": "Cancers",
  "versions": []
}